Kunhwa Kim, MD, MPH, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a post-hoc analysis of a Phase II trial (NCT03404193) investigating the outcomes of patients with TP53-mutant acute myeloid leukemia (AML) when treated with venetoclax plus decitabine in the frontline setting. The study found that TP53-mutant AML patients had a complete response (CR) rate of 35% to decitabine plus venetoclax therapy and a median overall survival (OS) of 5.2 months, compared to a CR of 57% and a median OS of 19.4 months in wild-type TP53 patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
